A preliminary study of functional imaging upon placebo analgesia in progressive multiple sclerosis
© Canellopoulou et al.; licensee BioMed Central Ltd. 2009
Published: 22 April 2010
In light of solid data regarding the extent of the placebo response as well as the rigorous arguments in favor of the randomized, placebo-controlled clinical trial, placebo analgesia has widely been tested and documented as one of the most robust placebo effects. Newly developed brain imaging tools such as functional magnetic resonance imaging (fMRI) have provided systematic evidence for the neurophysiological substrates involved in placebo analgesia [1, 2].
Materials and methods
In the present study, the replication of a well-documented expectancy manipulation model combined with a placebo intervention via acupuncture  was conducted to determine neural mechanisms underlying placebo analgesia in a group of 12 patients (6 females; mean age, 38.4 +/- 4.5 SD) with progressive multiple sclerosis (MS) matched for age, sex, duration of disease, disability and subjective pain ratings. Procedures involved two behavioral testing sessions and one fMRI scanning session as well as the administration of expectancy and pain subjective rating scales.
Subjective pain ratings indicated a significantly greater reduction in the placebo-control group as compared to the untreated condition (before/after treatment). The functional MRI signal difference between post-treatment and pre-treatment sessions was subtracted from the same difference in the non-treatment control group (post- and pre- placebo phases and post- and pre- control phases) indicating significant changes in mainly two of the so-called pain-sensitive brain regions such as the bilateral rostral anterior cingulated cortex (rACC) and the lateral prefrontal cortex.
Such findings are not consistent with research data from a wide range of neuropathies utilizing variant placebo treatments , suggesting that placebo analgesia as a result of expectancy can be detected in progressive multiple sclerosis yet, be subserved by the aforementioned brain regions. Future directions involve the study of brain activation patterns as a function of modality of placebo treatments with analgesic effects and identifying MS-specific forms of confounding as related to placebo analgesia.
- Levine D, Gordon NC, Fields HL: The mechanism of placebo analgesia. Lancet. 1978, 2: 654-657. 10.1016/S0140-6736(78)92762-9.View ArticlePubMedGoogle Scholar
- Benedetti F, Amanzio M: The specific effects of prior opioid exposure on placebo analgesia and placebo respiratory depression. Pain. 1998, 75: 313-319. 10.1016/S0304-3959(98)00010-4.View ArticlePubMedGoogle Scholar
- Kong J, Gollub RL, Rosman IS, Webb J, Vangel MG, Kirsch I, Kaptchuk TJ: Brain activity associated with expectancy-enhanced placebo analgesia as measured by functional magnetic resonance imaging. J Neurosci. 2006, 26 (2): 381-388. 10.1523/JNEUROSCI.3556-05.2006.View ArticlePubMedGoogle Scholar
- Hoffman GA, Harrington A, Fields HL: Pain and the placebo: what we have learned. Perspect Biol Med. 2005, 48: 248-265. 10.1353/pbm.2005.0054.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd.